FDA Grants Full Approval to Leqembi® and Medicare Expands Coverage
On Thursday, July 6, Leqembi® (lecanemab – irmb), became the first beta-amyloid targeting medication for the treatment of Alzheimer’s disease to receive full approval from the U.S. Food and Drug Administration (FDA). The drug, from pharmaceutical companies Eisai and Biogen, received [View More]









